nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

27.10.2023 | case report

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

A case report

verfasst von: Sophie Roider-Schur, Sybille Machat, Leopold Öhler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Evaluation of HER2 status and programmed death-ligand 1 (PD-L1) combined positive score (CPS) is mandatory in all patients with HER2-positive metastatic adenocarcinoma of the gastroesophageal junction (GEJ) not only to tailor first-line therapy but also to improve individual survival outcome. However, despite advances in the therapeutic management of metastatic adenocarcinoma of the GEJ, prognosis of these patients remains poor. We report a patient with HER2-positive metastatic adenocarcinoma of the GEJ who showed significant clinical and radiological benefit to HER2-directed therapy in the fifth-line therapeutic setting.

Vorheriger Artikel Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Nächster Artikel Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744–56. https://doi.org/10.1016/S1470-2045(23)00215-2.

Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/JCO.19.03077.

Gastric cancer. Lancet. 2020;396(10251):635–48.

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/S0140-6736(21)01234-4.

The KEYNOTE-811 trial of dual PD‑1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.

10.

Lorenzen S, Thuss-Patience PC, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO. J Clin Oncol. 2019;37:4023.CrossRef

11.

HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39(13):1468–78. https://doi.org/10.1200/JCO.20.02761.

Titel: Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
A case report
verfasst von: Sophie Roider-Schur
Sybille Machat
Leopold Öhler
Publikationsdatum: 27.10.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00928-8

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

Open Access
short review

Management of malignant hypercalcemia in cancer patients—a short review

short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Open Access
short review

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

short review

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Open Access
short review

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

editorial

Springer Medizin Österreich

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

A case report

Summary

Weitere Artikel der Ausgabe 4/2023

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

Management of malignant hypercalcemia in cancer patients—a short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

ASCO 2023—partnering with patients: the cornerstone of cancer care and research

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Imaging and therapy targeting PSMA receptors for enhanced vision and precise treatment

Management of malignant hypercalcemia in cancer patients—a short review

ASCO update—hepatocellular carcinoma and cholangiocellular carcinoma

Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

ASCO 2023—partnering with patients: the cornerstone of cancer care and research